• Cytek Biosciences narrowed its fiscal 2026 revenue forecast to $208 million-$211 million, maintaining the midpoint.
• The outlook implies revenue growth of 3%-5% year over year.
• Third-quarter revenue rose 2% to $53.2 million, driven by high-end instrument demand and service growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.